IGC · XBRL financial data

IGC Pharma financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (IGC's year ends in late December)

In thousands of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY25Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY26Jun 30, 2025	Q2 FY26Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	291	204	295*	272	412	257	330	328	191	350*	317	265
Cost of revenue	117	71	124*	109	214	153	176	174	92	306*	262	217
Gross profit	174	133	171*	163	198	104	154	154	99	44*	55	48
Research and development	1,268	903	855*	889	917	852	997	851	1,588	1,482*	1,272	1,390
Selling, general and administrative	1,397	2,228	1,486*	1,670	1,041	1,130	570	1,208	1,410	1,503*	1,241	1,442
Operating income (loss)	(2,491)	(2,998)	(2,170)*	(2,396)	(1,760)	(1,878)	(1,413)	(1,905)	(2,899)	(2,941)*	(2,458)	(2,784)
Interest expense	2*	1*	1*	1	2*	0*	2*	1	1*	2*	1	2*
Other income (expense)	40	32	7*	18	43	49	215	306	1,078	2,215*	56	(152)
Income tax expense (benefit)	0	0	0*	0	0	0	0	0	0	0*	0	0
Net income (loss)	(2,451)	(5,589)	(2,885)*	(2,378)	(1,717)	(1,829)	(1,198)	(1,599)	(1,821)	(726)*	(2,402)	(2,936)
Earnings per share, basic USD per share	(0.05)	(0.09)	(0.04)*	(0.03)	(0.02)	(0.02)	(0.02)	(0.02)	(0.02)	—	(0.02)	(0.03)
Earnings per share, diluted USD per share	(0.05)	(0.09)	—	(0.03)	(0.02)	(0.02)	(0.02)	(0.02)	(0.02)	—	(0.02)	(0.03)
Weighted average shares, basic thousands of shares	54,301	63,725	64,252*	72,814	76,007	77,633	79,658	83,027	90,458	—	98,162	100,331
Weighted average shares, diluted thousands of shares	54,301	63,725	—	72,814	76,007	77,633	79,658	83,027	90,458	—	98,162	100,331

Balance sheet

CSV

Fiscal quarters (IGC's year ends in late December)

In thousands of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY25Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY26Jun 30, 2025	Q2 FY26Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	3,026	1,378	1,198	1,824	1,546	470	405	454	1,105	900	207	331
Short-term investments	98	—	0	—	—	—	0	—	25	38	28	23
Accounts receivable	137	92	39	28	44	49	34	87	41	12	37	56
Inventory	2,636	1,925	1,540	1,510	1,510	1,433	1,360	1,349	658	640	638	640
Prepaid and other current assets	220	188	208	325	434	398	395	212	175	200	237	214
Total current assets	6,117	3,583	3,705	4,407	4,250	3,051	2,896	2,153	2,004	1,790	1,147	1,264
Property and equipment, net	7,947	5,268	3,695	3,586	3,468	3,348	3,220	3,097	2,175	2,141	2,103	2,069
Right-of-use asset	263	227	198	193	161	129	98	16	13	11	8	0
Total assets	16,506	11,259	9,902	10,594	10,369	9,078	8,747	7,943	9,743	9,712	9,185	9,496
Accounts payable	549	648	773	771	768	835	883	933	628	1,014	1,255	1,618
Accrued liabilities	1,557	1,288	1,567	1,718	2,034	1,822	1,374	792	886	1,142	892	664
Total current liabilities	2,106	1,936	2,340	2,489	2,802	2,657	2,257	1,725	1,514	2,156	2,873	3,215
Long-term debt	139	138	137	136	135	134	134	133	132	131	—	—
Lease liability, non-current	146	115	84	69	35	12	10	7	5	2	—	—
Total liabilities	2,408	2,206	2,581	2,714	2,992	2,819	2,417	1,865	1,651	2,289	3,064	3,364
Accumulated deficit	(105,191)	(110,780)	(113,665)	(116,043)	(117,760)	(119,589)	(120,744)	(122,343)	(122,828)	(124,890)	(127,292)	(130,228)
Total stockholders' equity	14,098	9,053	7,321	7,880	7,377	6,259	6,330	6,078	8,092	7,423	6,121	6,132
Total liabilities and equity	16,506	11,259	9,902	10,594	10,369	9,078	8,747	7,943	9,743	9,712	9,185	9,496
Common shares outstanding (cover page) thousands of shares	63,734	63,734	75,636	75,636	77,449	79,685	83,892	90,809	92,868	98,796	100,091	103,384

Cash flows

CSV

Fiscal quarters (IGC's year ends in late December)

In thousands of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 31, 2023	Q4 FY24Mar 31, 2024	Q1 FY25Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY26Jun 30, 2025	Q2 FY26Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,451)	(5,589)	(2,885)*	(2,378)	(1,717)	(1,829)	(1,198)	(1,599)	(1,821)	(726)*	(2,402)	(2,936)
Stock-based compensation	—	—	year only	4,600	0*	(300)*	0*	4,700	0*	(100)*	4,000	200*
Depreciation and amortization	158*	160*	164*	162	145*	157*	154	141	119*	64*	58	56*
Net cash from operating activities	(1,618)*	(1,587)*	(526)*	(1,752)	(996)*	(1,317)*	(730)	(1,407)	(2,090)*	(1,223)*	(1,223)	(1,350)*
Purchases of property and equipment	35*	68*	15*	38	29*	27*	18	8	29*	12*	1	5*
Net cash from investing activities	72*	(61)*	(323)*	(131)	(65)*	(104)*	(142)	580	(374)*	(228)*	(170)	(254)*
Proceeds from issuing common stock	2,860*	0*	167*	2,508	795*	346*	805	852	3,111*	—	87	1,039*
Proceeds from issuing equity	2,860*	0*	—	—	—	—	—	—	—	—	—	—
Proceeds from long-term debt	—	—	—	—	—	—	0	—	—	—	623	—
Repayments of long-term debt	—	—	—	—	—	1*	0*	—	—	1*	—	—
Net cash from financing activities	2,859*	(1)*	667*	2,507	794*	345*	805	851	3,110*	1,264*	710	1,730*
Net change in cash	1,303*	(1,648)*	(180)*	626	(278)*	(1,076)*	(65)	49	651*	(205)*	(693)	124*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
IGC Pharma	331	265	(1,350)*	103.4M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Cognition Therapeutics	34,012	not reported	(3,053)*	95.1M	11.1 quarters	Q2 FY26 10-QJun 30, 2026
Relmada Therapeutics	11,334	not reported	(9,606)*	106.7M	22.7 quarters	Q2 FY26 10-QJun 30, 2026
CEL-SCI	6,527	not reported	(4,031)*	17.6M	1.6 quarters	Q3 FY26 10-QJun 30, 2026
Charlie's Holdings	527	not reported	(383)*	280.6M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Ernexa Therapeutics	5,028	not reported	(4,152)*	1.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Marker Therapeutics	11,331	not reported	(3,716)*	16.7M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Lipocine	4,979	190	(3,028)*	8.2M	7.7 quarters	Q2 FY26 10-QJun 30, 2026
Fibrogen	50,644	(1,474)	(3,991)*	4.0M	22.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.